In Brief: Cortecs/Exocell
This article was originally published in The Gray Sheet
Executive Summary
Cortecs/Exocell: Firms sign collaboration agreement for the development of a series of point-of-care diagnostic test kits to assist in monitoring and treatment of diabetes using whole blood, plasma or serum by measuring glycated protein content. Under the terms of the deal, London-based Cortecs' rapid diagnostic technologies would be combined with "expertise, reagents and antibodies" provided by Philadelphia-based Exocell. Exocell would handle U.S. regulatory issues and Cortex would manufacture the products...